FDA Clears NeuroQuant PET Software for Automated Alzheimer's Amyloid Quantification
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Cortechs.ai for its NeuroQuant PET platform. This software automates the quantification of amyloid plaques in positron emission tomography (PET) scans, which are crucial for diagnosing Alzheimer's disease and related neurocognitive disorders. Traditionally, radiologists visually interpret these scans, leading to potential variability in judgment. NeuroQuant PET aims to standardize this process by mapping brain regions, calculating standardized uptake value ratios, and converting results into Centiloids. This unit allows for consistent comparison of scans regardless of the tracer or scanner used. The software is compatible with three widely used amyloid tracers (flutemetamol, florbetaben, and florbetapir) and integrates with existing PET-CT, PET-MR, and PET-only setups. This development represents a shift from subjective, phenotype-based assessments to a more objective, biomarker-driven approach in neurodegenerative disease evaluati...